AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceNamed GroupsHealth Care
Remission InductionTransplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyCombined Modality TherapyPeripheral Blood Stem Cell TransplantationMelphalanMultiple MyelomaTreatment OutcomeTransplantation, HomologousTransplantation ConditioningCytarabineDisease-Free SurvivalCyclophosphamideEtoposideSalvage TherapyVincristineRecurrenceSurvival RateStem CellsSurvival AnalysisHodgkin DiseaseLymphoma, Non-HodgkinBone Marrow TransplantationDoxorubicinPrognosisLeukemia, Myeloid, AcuteMyeloablative AgonistsCarmustineHematopoietic Stem Cell MobilizationThiotepaGraft vs Host DiseaseAntineoplastic AgentsCisplatinBone Marrow PurgingRetrospective StudiesFollow-Up StudiesHematologic NeoplasmsDexamethasonePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoneIdarubicinChemotherapy, AdjuvantWhole-Body IrradiationIfosfamideLymphoma, Mantle-CellTime FactorsNeoplasm, ResidualAmyloidosisHematopoietic Stem CellsBusulfanDaunorubicinBoronic AcidsLeukemia, MyeloidAntibodies, Monoclonal, Murine-DerivedPyrazinesAntineoplastic Agents, AlkylatingGraft SurvivalGranulocyte Colony-Stimulating FactorLymphoma, FollicularDrug Administration ScheduleMethotrexateAntigens, CD34AsparaginaseLymphoma, T-Cell, PeripheralAutograftsThalidomideCarboplatinLymphomaLiver TransplantationAcute DiseaseRemission, SpontaneousLeukapheresisProspective StudiesBone MarrowMesenchymal Stem Cell TransplantationNeoplasm StagingPodophyllotoxinLeukemiaMaintenance ChemotherapyLymphoma, Large B-Cell, DiffuseMitoxantroneNeoplasm Recurrence, LocalTransplantation ChimeraMyelodysplastic SyndromesAntibodies, MonoclonalTissue DonorsCord Blood Stem Cell TransplantationNeutropeniaLymphoma, B-CellCell TransplantationClinical Trials as TopicFeasibility StudiesNeoplasms, Second PrimaryKidney TransplantationBreast NeoplasmsEmbryonic Stem CellsEnteropathy-Associated T-Cell Lymphoma
Acute lymphocyRegimensRelapsePeripheralTransplantHematopoietic cell transplantationRituximabLymphomaASCTImmunotherapyTherapy and autologousBoneAllogeneic and autologousSurvivalCohortDaunorubicinDeeper remissionAcquired resistance to chemotherapyEtoposideMalignancyPBSCTRadiotherapyIntrathecal chemotherapyCompleteLymphomasRefractory diseaseCytarabineLeukemiaConsolidation chemotherapyTreatmentTherapiesRadiation therapyTherapeuticBlood stemArsenic trioxideATRAMalignantMyelomaMedianTumor cellsMitoxantroneNewly diagnosedCombinationDiagnosisFeasibilityEligible
Acute lymphocy2
  • Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). (ashpublications.org)
  • Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. (medscape.com)
Regimens8
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • Thus, I think that the lesson that should be taken from the intensive approaches is that treatment regimens that provide MRD-negative complete remission states in high percentages will likely be associated with better outcomes as compared with regimens that do not, and, therefore, we should at least consider that potential. (expertperspectives.com)
  • We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. (ashpublications.org)
  • Current standard chemotherapy regimens cure only a minority of patients with AML. (medscape.com)
  • Various acceptable induction regimens are available. (medscape.com)
  • On these regimens, approximately 50% of patients achieve remission with one course. (medscape.com)
  • [ 35 ] These induction regimens were administered with cytarabine 100 mg/m 2 /d for 7 days for the first cycle. (medscape.com)
Relapse9
  • Consolidation therapy is based on the potential risk of relapse in patients who undergo induction therapy. (medscape.com)
  • Some patients may not respond to chemotherapy at all while few patients respond initially but later on relapse. (lymphomaindia.com)
  • Early features such as stem cell properties has long been proven to be linked to early relapse in AML. (ghrnet.org)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Therapeutic Candidate or Device TriLeukeVax, an autologous AML vaccine designed to stimulate induction of anti-leukemic cytolytic activity and improve relapse free survival (RFS). (ca.gov)
  • The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. (biomedcentral.com)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • 3 The course of the disease is typically one of recurrent remission and relapse. (bmj.com)
  • 1,2 One of the issues is that three-quarters of the patients who did not receive ASCT initially had a stem cell transplant at first relapse. (targetedonc.com)
Peripheral13
Transplant13
  • During the COVID-19 outbreak, planned autologous stem cell transplant (ASCT) for patients may be postponed to a more suitable time. (mpeurope.org)
  • The study involved analysis of data from 519 patients with chemotherapy-sensitive mantle cell lymphoma receiving transplantations between 1996 and 2007 who were reported to the Center for International Blood and Marrow Transplant Research. (ascopost.com)
  • Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. (canceropole-est.org)
  • Following that, patients may be eligible for a stem cell transplant, and/or an extended course of immunotherapy that is meant to prolong cancer remission. (rarediseases.org)
  • Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). (haematologica.org)
  • 1 Despite significant therapeutic advances for MM, autologous stem cell transplant (ASCT) following high-dose, single-agent melphalan conditioning remains a cornerstone of therapy. (haematologica.org)
  • Would you recommend autologous stem cell transplantation (ASCT) for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)? (targetedonc.com)
  • Then, patients in 1 group received another 5 cycles of VRd] and patients in the other had a stem cell transplant followed by 2 more cycles of VRd. (targetedonc.com)
  • 2 Even though I was trained by somebody who's not the biggest fan of doing stem cell transplants, this is something that needs to be mentioned as most people ended up getting a transplant. (targetedonc.com)
  • The subgroup analysis by minimal residual disease [MRD] status, or by risk status, showed that the patients with high-risk cytogenetics seemed to derive less benefit from high-dose chemotherapy and a stem cell transplant, 2 which is the opposite of what you would expect. (targetedonc.com)
  • lenalidomide-dexamethasone [KRd] or with cyclophosphamide-dexamethasone [KCd], with half the patients getting KRd, just continuing without a transplant, and the others doing a stem cell transplant and then getting some further therapy afterward. (targetedonc.com)
  • Syed A. Abutalib, MD , of Cancer Treatment Centers of America, and Nelli Bejanyan, MD , of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and Marrow Transplant Research on treatment for ALL patients, with an available donor, undergoing myeloablative allogeneic hematopoietic cell transplantation in first complete remission (Abstract 684). (ascopost.com)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
Hematopoietic cell transplantation4
  • Therapeutic Candidate or Device OSSM007: cryopreserved, interferon-gamma-primed bone marrow mesenchymal stem cells (BM-MSC) Indication acute Graft versus host disease (aGVHD) resulting from hematopoietic cell transplantation Therapeutic Mechanism Immunomodulation of host-reactive T cells to induce operational tolerance of donor HSC-derived lymphocytes through direct cell-to-cell contact and secreted paracrine factors. (ca.gov)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • The Japanese Society of Hematopoietic Cell Transplantation (JSHCT) has been conducting a nationwide survey on HCT since 1993, in which HCTs performed at participating centers are registered with the JSHCT every year. (apbmt.org)
Rituximab7
  • The primary objective is to demonstrate that intensified chemotherapy followed by consolidating HCT-ASCT is superior to conventional chemotherapy with rituximab, MTX, procarbazine (R-MP) followed by maintenance with procarbazine in terms of progression free survival (PFS). (biomedcentral.com)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • Rituximab should be combined with the chemotherapy for more efficient cancer cell kill. (lymphomaindia.com)
  • On multivariate analysis of overall survival from the time of diagnosis, stem cell transplantation beyond first complete response, greater age (≥ 60 years), no rituximab prior to transplantation, and increased lactate dehydrogenase at diagnosis were associated with significantly inferior survival. (ascopost.com)
  • Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. (canceropole-est.org)
  • Umberto Vitolo, MD , of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD , of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470). (ascopost.com)
  • Steven Le Gouill, MD, PhD , of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145). (ascopost.com)
Lymphoma33
  • DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. (wikipedia.org)
  • Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. (expertperspectives.com)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for more than 30 percent of newly diagnosed cases. (lymphomaindia.com)
  • Another example is "primary mediastinal B-cell lymphoma" which often occurs in younger patients and grows rapidly in the chest (mediastinum) Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, or groin, which is caused by enlarged lymph nodes. (lymphomaindia.com)
  • Follicular lymphoma (FL), a B-cell lymphoma, is the most common indolent (slow-growing) form of NHL, accounting for approximately 20 percent to 30 percent of all NHLs. (lymphomaindia.com)
  • Approximately 30-40 % of patients with FL will eventually transform to a more aggressive form of lymphoma like Diffuse Large B Cell Lymphoma and may require intensive chemotherapy followed by autologous stem cell transplantation. (lymphomaindia.com)
  • In an analysis reported in the Journal of Clinical Oncology , Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. (ascopost.com)
  • The image below shows pre-B-cell lymphoblastic leukemia/lymphoma (B-ALL). (medscape.com)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. (canceropole-est.org)
  • P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma. (cancernetwork.com)
  • This article reviews the current data and future directions in the management of Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL). (cancernetwork.com)
  • BL is a rare, mature B-cell lymphoma molecularly defined by translocation of the proto-oncogene MYC. (cancernetwork.com)
  • HGBL, not otherwise specified (NOS) is a heterogeneous, aggressive, mature B-cell lymphoma that does not meet criteria for BL, DHL, or diffuse large B-cell lymphoma NOS. (cancernetwork.com)
  • 1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, which is a form of cancer that affects the lymphatic system. (rarediseases.org)
  • MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. (rarediseases.org)
  • Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. (oncotarget.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare mature T-cell malignancy first described in Japan in 1977 [ 1 ]. (oncotarget.com)
  • Lymphoma is the most common haematopoietic malignancy in dogs, and is the most responsive to chemotherapy. (vin.com)
  • Most veterinary oncologists agree that unless palliation rather than extended remission is the goal of therapy, single agent treatment of lymphoma should be avoided. (vin.com)
  • Overall, COP chemotherapy causes complete remission in about 70% of dogs with lymphoma for a median of 130 days. (vin.com)
  • Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Hodgkin lymphoma results from the clonal transformation of cells of B-cell origin, giving rise to pathognomic binucleated Reed-Sternberg cells. (msdmanuals.com)
  • Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. (lookformedical.com)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. (sc-ctsi.org)
  • It is used as a form of chemotherapy for malignancies such as lung cancer, testicular cancer, lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme. (the-medical-dictionary.com)
ASCT4
  • High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. (biomedcentral.com)
  • A randomized controlled trial, incorporating a GA and comparing age-adapted HCT-ASCT treatment with conventional chemotherapy is needed. (biomedcentral.com)
  • 3 Patients achieving deeper remission receive the greatest duration of clinical benefit following ASCT. (haematologica.org)
  • San Diego, CA-Although considered a standard of care for patients with newly diagnosed multiple myeloma, the benefit of autologous stem-cell transplantation (ASCT) has been recently questioned as a result of the rapid expansion of novel treatments. (valuebasedcancer.com)
Immunotherapy4
  • Multiagent chemotherapy + immunotherapy should be reserved for patients who are having advanced stages of disease and having symptoms/ difficulties related to it. (lymphomaindia.com)
  • The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)
  • Treatment is curative in most cases and consists of chemotherapy with or without other treatment modalities, including antibody-drug conjugates, immunotherapy, and radiation therapy. (msdmanuals.com)
  • Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. (wustl.edu)
Therapy and autologous2
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • Although there was evidence of a response to CTD (M-protein 34 g/L), bortezomib and dexamethasone treatment was initiated as an alternative, but this was discontinued after three cycles due to progressive disease (M-protein 49 g/L). The patient was then treated with lenalidomide and dexamethasone with the aim of reducing disease burden prior to high-dose therapy and autologous stem cell transplantation. (bmj.com)
Bone23
  • the ATO dosage is 0.15 mg/kg/day IV until bone marrow remission occurs (maximum induction, 60 doses). (medscape.com)
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
  • The transferred, expanded natural killer cells proliferated in vivo in an interleukin-2 dose-dependent fashion, persisted up to 4 weeks, were readily detectable in the human bone, inhibited myeloma growth and protected bone from myeloma-induced osteolysis. (haematologica.org)
  • Multiple myeloma (MM) is a malignant plasma cell disorder with debilitating symptoms related to anemia, immunosuppression, bone destruction, and renal failure. (haematologica.org)
  • Acute myeloid leukemia (AML) results from the over-proliferation of progenitor cells of the myeloid lineage in the bone marrow. (ghrnet.org)
  • Acute lymphoblastic leukemia (ALL): Bone marrow shows proliferation of large and heterogeneous lymphoblasts consistent with pre-B-cell ALL (French-American-British L2 morphology). (medscape.com)
  • Therapeutic Candidate or Device Autologous hematopoietic stem cells transduced with a HexA/HexB expressing lentiviral vector Indication Tay-Sachs disease Therapeutic Mechanism The transplanted gene modified autologous hematopoietic stem cells will engraft in the bone marrow and start producing HexA/HexB expressing immune progeny. (ca.gov)
  • Lymphatic tissues also include the thymus, a relatively small organ behind the breastbone that is thought to play an important role in the immune system until puberty, as well as the bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites. (lookformedical.com)
  • Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. (lookformedical.com)
  • Adult acute myeloid leukemia (AML) is a disease in which cancer (malignant) cells are found in the blood and bone marrow. (marystolfacancerfoundation.org)
  • The bone marrow makes red blood cells (which carry oxygen and other materials to all tissues of the body), white blood cells (which fight infection), and platelets (which make the blood clot). (marystolfacancerfoundation.org)
  • Normally, the bone marrow makes cells called blasts that develop (mature) into several different types of blood cells that have specific jobs to do in the body. (marystolfacancerfoundation.org)
  • These immature blast cells are then found in the blood and the bone marrow. (marystolfacancerfoundation.org)
  • There are too many white blood cells in the blood and bone marrow, and there may be other signs and symptoms of leukemia. (marystolfacancerfoundation.org)
  • Treatment has been given, and the number of white blood cells and other blood cells in the blood and bone marrow is normal. (marystolfacancerfoundation.org)
  • Bone marrow transplantation and biological therapy are being studied in clinical trials. (marystolfacancerfoundation.org)
  • Bone marrow transplantation is used to replace the bone marrow with healthy bone marrow. (marystolfacancerfoundation.org)
  • First, all of the bone marrow in the body is destroyed with high doses of chemotherapy with or without radiation therapy. (marystolfacancerfoundation.org)
  • Myeloma is a B-cell malignancy that is characterised by the monoclonal expansion and accumulation of abnormal plasma cells within the bone marrow. (bmj.com)
  • Multiple Myeloma is a type of blood cancer affecting the bone marrow predominantly and is characterised by excessive multiplication of a type of white blood cells called plasma cells. (singhealthdukenus.com.sg)
  • The cancer cells may overwhelm the normal bone marrow functions and prevent it from making enough healthy blood cells. (singhealthdukenus.com.sg)
  • Secondly, the myeloma cells may also damage and weaken the bone, make it friable such that it may fracture with even trivial injury or release calcium from the bones into the blood causing dangerously high blood levels of this element. (singhealthdukenus.com.sg)
Allogeneic and autologous2
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
  • Figure 1 shows the trend in the annual number of allogeneic and autologous HCTs in adults with AML reported in the Japanese transplantation registry. (apbmt.org)
Survival17
  • BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of selected patients with peritoneal metastasis. (bvsalud.org)
  • A higher rate of complete remission was observed in the high-dose daunorubicin group (70.6%) relative to the conventional dose (57.3%) as well as an improved overall survival (median, 23.7 mo) compared with the group administered the conventional dose (15.7 mo). (medscape.com)
  • Although survival endpoints did not differ overall, there was an improvement in complete remission rate, event-free survival, and overall survival in patients aged 60-65 years. (medscape.com)
  • However, 2 studies demonstrated improved disease-free survival rates in younger patients who received high-dose cytarabine during induction. (medscape.com)
  • Prognostic markers predict treatment related mortality (TRM), resistance to chemotherapy or survival. (ghrnet.org)
  • There were no significant differences in 5-year overall survival for autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in the early transplantation cohort or in the late cohort. (ascopost.com)
  • Survival was significantly better for both procedures when transplantation occurred earlier in the disease course. (ascopost.com)
  • Five-year overall survival was similar for the autologous vs the allogeneic transplantation groups in the early cohort (61% vs 62%, P = .951) and in the late cohort (44% vs 31%, P = .202). (ascopost.com)
  • Survival was significantly better in patients in the early cohort among both autologous ( P = .004) and allogeneic transplantation patients ( P = .005). (ascopost.com)
  • Among autologous transplantation recipients, 5-year overall survival was 75% in patients with first complete response with one line of pretransplantation therapy, 70% in those with first complete response with two lines of therapy, and 38% in those with primary induction failure-sensitive disease (partial remission with no history of complete response). (ascopost.com)
  • In the autologous transplantation group, survival was greater with early vs late transplantation (relative risk [RR] of death = 0.70, P = .037). (ascopost.com)
  • There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. (oncotarget.com)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Metastatic triple negative breast cancer (TNBC), urothelial, and non-small cell lung cancer (NSCLC) are solid tumor malignancies with abysmal survival rates following progression on initial therapies. (fredhutch.org)
  • Metastatic pancreatic cancer patients have a mean survival of 6 months following progression on initial first line chemotherapy. (fredhutch.org)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • San Diego, CA-Maintenance therapy with lenalidomide (Revlimid) after frontline chemotherapy markedly prolonged progression-free survival (PFS) in patients with high-risk chronic lymphocytic leukemia (CLL), according to interim results from a phase 3 study presented at the 2016 American Society of Hematology meeting. (valuebasedcancer.com)
Cohort6
Daunorubicin3
Deeper remission5
  • The concept of a deeper remission and its significance in MCL is somewhat debatable. (expertperspectives.com)
  • The first question is: To what extent does a deeper remission matter? (expertperspectives.com)
  • Evidence showing that a deeper remission may matter in MCL comes largely from studies of patients who received intensive induction chemotherapy and proceeded to autologous stem cell transplantation, where MRD negativity was associated with better outcomes. (expertperspectives.com)
  • Now, a critique of MRD-driven therapy would be that achieving a deeper remission is associated with improved outcomes but does not actually cause them (eg, MRD negativity might simply be a marker of more easily treated disease). (expertperspectives.com)
  • The best definition of a deeper remission is one in which the patient is MRD negative and is in complete remission by imaging studies. (expertperspectives.com)
Acquired resistance to chemotherapy1
  • In patients, primary or acquired resistance to chemotherapy is associated with the expression of P-gp. (ashpublications.org)
Etoposide2
Malignancy2
  • Multiple Myeloma (MM) is an incurable plasma cell malignancy that accounts for 18% of all hematologic malignancies. (haematologica.org)
  • A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. (lookformedical.com)
PBSCT2
  • In cases of unrelated HCT, PBSC transplantation (PBSCT) still comprises only a very small percentage, which reflects the fact that unrelated PBSCT did not come into use in Japan until 2010. (apbmt.org)
  • Conclusion: Double-cycle, high-dose ICE therapy followed by PBSCT is tolerable and feasible even after conventional chemotherapy or chemoradiotherapy in patients with SCLC. (the-medical-dictionary.com)
Radiotherapy3
  • For decades the only available cancer treatments were surgical resection as well as chemotherapy and/or radiotherapy [ 1 ]. (nature.com)
  • Further, cancer treatment often involves radiotherapy and chemotherapy, which not only kills cancer cells but also affects healthy cells. (aspetjournals.org)
  • For instance, the use of 131 I radiotherapy to treat thyroid cancer is highly dependent on the selective expression of the sodium/iodine symporter on these cells ( Kogai and Brent, 2012 ). (aspetjournals.org)
Intrathecal chemotherapy3
  • Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. (ashpublications.org)
  • Chemotherapy may sometimes be put into the fluid that surrounds the brain through a needle in the brain or back (intrathecal chemotherapy). (marystolfacancerfoundation.org)
  • If the leukemia cells have spread to the brain, radiation therapy to the brain or intrathecal chemotherapy will be given. (marystolfacancerfoundation.org)
Complete12
  • Treatment with ATRA should be continued until terminal differentiation of blasts and achievement of complete remission. (medscape.com)
  • This combination seems to have a higher complete remission rate and MRD-negative rate than the BTK inhibitor alone, suggesting that such a regimen would be appropriate to study further. (expertperspectives.com)
  • They must have achieved complete remission (CR), lasting at least three months with their last induction regimen and they must have relapsed after the last regimen. (stanford.edu)
  • The complete remission rate was 64% in the escalated-dose group compared with 54% in conventional-dose group. (medscape.com)
  • The treatment usually involves a remission induction phase aimed at establishing a complete remission and a postinduction phase aimed at eradicating "occult" residual disease. (ashpublications.org)
  • These combinations induce complete remissions (CR) in an average of 70% to 80% of adults aged less than 60 years. (ashpublications.org)
  • Patients achieving partial or complete remission may receive a second course of therapy beginning approximately 30 days after the completion of the first course. (knowcancer.com)
  • This approach is meant to cause complete or partial disappearance of the cancer (remission). (rarediseases.org)
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
  • Complete remission was achieved in 84% of dogs for a median of about 9 months. (vin.com)
  • Although 131 I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. (biomedcentral.com)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
Lymphomas3
  • BACKGROUND: Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. (bvsalud.org)
  • The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)
  • Lymphomas are cancers that involve white blood cells, and can be divided depending on the type of cell involved, either B-lymphocytes or T-lymphocytes. (rarediseases.org)
Refractory disease2
Cytarabine3
Leukemia10
  • Induction therapy should not be modified based on the presence of leukemia cell characteristics that have variably been considered to predict a poorer prognosis (eg, secondary chromosomal abnormalities, FLT3 mutations, CD56 expression, BCR3 PML-RARA isoform). (medscape.com)
  • ADDITIONAL BACKGROUND: S0919 was initially designed for patients with relapsed acute myeloid leukemia (AML), where the patient's preceding remission had lasted ≥ 3 months. (stanford.edu)
  • Patients must have received at least one prior chemotherapy regimen for their acute myeloid leukemia (AML) and they may have received any type of chemotherapy. (stanford.edu)
  • Although the incidence of acute nonlymphocytic leukemia is increased in PV, the incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low. (basicmedicalkey.com)
  • Interestingly, chemotherapy, including hydroxyurea, has been associated with acute leukemia in JAK2 V617F-negative stem cells in some PV patients. (basicmedicalkey.com)
  • Leukemia can be acute (progressing quickly with many immature blasts) or chronic (progressing slowly with more mature looking cancer cells). (marystolfacancerfoundation.org)
  • and Hairy Cell Leukemia Treatment for more information. (marystolfacancerfoundation.org)
  • Recurrent disease means the leukemia has come back after going into remission. (marystolfacancerfoundation.org)
  • The purpose of induction therapy is to kill as many of the leukemia cells as possible and make patients go into remission. (marystolfacancerfoundation.org)
  • Once in remission with no signs of leukemia, patients enter a second phase of treatment (called continuation therapy), which tries to kill any remaining leukemia cells. (marystolfacancerfoundation.org)
Consolidation chemotherapy1
  • For consolidation chemotherapy or for the management of toxic effects of chemotherapy, readmission is required. (medscape.com)
Treatment14
  • Treatment of APL includes induction therapy, consolidation therapy, and maintenance therapy. (medscape.com)
  • Stopping treatment altogether, where clinically appropriate to do so (e.g. where a patient is in good remission). (mpeurope.org)
  • Dr. Löwenberg describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers and reviews experimental strategies to improve remission induction and postinduction treatment. (ashpublications.org)
  • Continuous efforts are being made to improve the efficacy of remission induction treatment. (ashpublications.org)
  • Indication AiPSC-RPE cell product will be indicated for the treatment of maculopathies related to RPE atrophy. (ca.gov)
  • Prognostic factors include stage and substage of disease, histologic type, immunophenotype (B-cell versus T-cell), presence of hypercalcemia, response to therapy, pre-treatment steroid therapy, and possibly gender. (vin.com)
  • There are currently few treatment options and include strategies such as second-line chemotherapy with response rates averaging 10%, median PFS of 3 months and OS of 6 months. (fredhutch.org)
  • PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. (med-abstracts.com)
  • Data presented at the 2016 American Society of Hematology meeting show that it is possible for some patients with CML to reduce their TKI dose by 50% and maintain remission, perhaps even stop treatment altogether once deep and durable remission has been achieved after approximately 5 years of treatment. (valuebasedcancer.com)
  • The primary treatment of AML is chemotherapy. (marystolfacancerfoundation.org)
  • Chemotherapy is called a systemic treatment because the drug enters the bloodstream, travels through the body, and can kill cancer cells throughout the body. (marystolfacancerfoundation.org)
  • While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. (bmj.com)
  • However, patients progressively acquire resistance to treatment and subsequent remissions become shorter and shorter. (bmj.com)
  • Treatment was frequently interrupted and dose adjusted to account for neutropenia and despite a minor response after six cycles (starting M-protein 47 g/L, finishing M-protein 34 g/L), in October 2009, she proceeded with stem cell mobilisation. (bmj.com)
Therapies8
  • This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection. (biomedcentral.com)
  • For these patients, following additional therapies are often successful in providing another remission. (lymphomaindia.com)
  • Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
  • Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
  • In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
  • Six such CAR-T cell therapies are approved by the Food and Drug Administration. (wustl.edu)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • We decided to perform cord blood stem cell transplantation (CBSCT) for hematopoietic rescue after the myeloablative therapies. (biomedcentral.com)
Radiation therapy1
Therapeutic6
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • Therapeutic Candidate or Device Autologous blood stem cells edited to restore iduronidase expression Indication Severe Mucopolysaccharidosis Type 1 (MPS1/ Hurler's syndrome) Therapeutic Mechanism Autologous blood stem cells undergo genome editing to restore the production of the missing enzyme. (ca.gov)
  • Therapeutic Candidate or Device Hematopoietic stem and progenitor cells collected from X-CGD patients modified with a highly regulated lentiviral vector Indication X-linked Chronic Granulomatous Disease Therapeutic Mechanism Lentiviral vector (LV) modification of autologous hematopoietic stem and progenitor cells (HSPCs) to restore physiologic gp91phox expression. (ca.gov)
  • In a phase I trial, we seek to determine the safety and potential efficacy of this T cell therapy in addition to an FDA approved therapeutic standard anti-PD-L1 therapeutic, atezolizumab, for patients with advanced triple negative breast cancer, urothelial, or non-small cell lung cancers whose tumors express high level of MAGE-A1 and have become resistant to PD-L1 axis treatments. (fredhutch.org)
  • Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
Blood stem1
Arsenic trioxide2
  • For low- and intermediate-risk patients, induction therapy should consist of ATRA and arsenic trioxide (ATO) without chemotherapy. (medscape.com)
  • In the past two decades, therapy for newly diagnosed APL has evolved from an all- trans retinoic acid (ATRA)+chemotherapy backbone for all patients to the addition of arsenic trioxide (ATO) to ATRA with omission of chemotherapy in low-risk patients as a new standard of care. (nature.com)
ATRA4
  • ATRA and anthracycline-based chemotherapy is an option when ATO is contraindicated or unaffordable. (medscape.com)
  • ATRA plus ATO with a certain amount of chemotherapy is a possible option, but ATO is not approved for use in high-risk patients. (medscape.com)
  • Furthermore, with ATRA-ATO combinations, chemotherapy may safely be omitted in low-risk patients. (nature.com)
  • The major component of induction therapy is all-trans retinoic acid (ATRA), which is commonly combined with other agents. (medscape.com)
Malignant4
  • The malignant cells of ALL are lymphoid precursor cells (ie, lymphoblasts) that are arrested in an early stage of development. (medscape.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
  • CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)
Myeloma4
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • As the number of myeloma cells increases, fewer red blood cells, white blood cells, and platelets are made. (singhealthdukenus.com.sg)
Median1
Tumor cells4
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • Transporters on the plasma membrane of tumor cells are promising molecular "Trojan horses" to deliver drugs and imaging agents into cancer cells. (aspetjournals.org)
  • A cell line derived from cultured tumor cells. (lookformedical.com)
  • Rarely, tumor cells can appear as a solid tumor called an isolated granulocytic sarcoma or chloroma. (marystolfacancerfoundation.org)
Mitoxantrone1
Newly diagnosed1
  • Harry P. Erba, MD, PhD , of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML (Abstract 211). (ascopost.com)
Combination2
  • Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
  • Radioimmunotherapy (RIT) alone or in combination with chemotherapy: Two radioimmunotherapy drugs are commercially available: Iodine 131 tositumomab (Bexxar) and Y90 ibritumomab tiuxetan (Zevalin). (lymphomaindia.com)
Diagnosis2
  • At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. (ashpublications.org)
  • Other laboratory studies that may aid in diagnosis include the red cell count, mean corpuscular volume, and red cell distribution width (RDW), particularly when the hematocrit or hemoglobin levels are less than 60% or 20 g/dL, respectively. (basicmedicalkey.com)
Feasibility1
  • The safety and feasibility of administering autologous engineered WT1-specific T cells as post-remission AML therapy will be assessed in this study. (fredhutch.org)
Eligible1